Digilab Peptidomics receives United States Patent for Alzheimer's Disease Biomarkers
Digilab Peptidomics®, formerly BioVisioN, was granted a patent by the US Patent Office for a new panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases. Using proprietary Peptidomics®-Technologies, scientists from Digilab Inc have discovered a group of Osteonpontin marker peptides that correlates to Alzheimer's disease, Vascular Dementia, and Parkinson's disease. A method for early and reliable detection based on Digilab's Peptidomics® biomarkers will enable the development of novel therapies for this segment of CNS diseases with debilitating patient care medical consequences.
Dementia diseases represent an increasing problem in industrialized countries because of higher average life expectancies. Such diseases are in most cases incurable and patients therefore require long-term care. Half of these patients receive in-patient care. Alzheimer's Disease accounts for about 65% of chronic dementias and new methods for diagnosis and therapy are therefore of great importance.
Diglab's scientists believe these new Peptidomics® biomarkers will be an alternative or supplementary method to the mini-mental score. "An earlier, faster, easier and safer method for the diagnosis of chronic dementia diseases would save invaluable time to start proper treatment", commented Dr. Hans-Dieter Zucht, Chief Technology Officer at Digilab, "Our patented peptide biomarkers avoid the diagnosis disadvantages of prior art for such diseases".
Other news from the department research and development
